CoChat

Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial

Open access

The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.

Abstract

Cirrhosis is a major cause of morbidity and mortality; however, there are no approved therapies except orthotopic liver transplantation. Preclinical studies showed that bone-marrow-derived macrophage injections reduce inflammation, resolve fibrosis and stimulate liver regeneration. In a multicenter, open-label, parallel-group, phase 2 randomized controlled trial ( ISRCTN10368050 ) in n = 51 adult patients with compensated cirrhosis and Model for End-Stage Liver Disease (MELD) score ≥10 and ≤17, we evaluated the efficacy of autologous monocyte-derived macrophage therapy ( n = 27) compared to standard medical care ( n = 24). The primary endpoint was the difference in baseline to day 90 change in MELD score (ΔMELD) between treatment and control groups (ΔΔMELD). Secondary endpoints included adverse clinical outcomes, non-invasive fibrosis biomarkers and health-related quality of life (HRQoL) at 90 d, 180 d and 360 d. The ΔΔMELD between day 0 and day 90 in the treatment group compared to controls was −0.87 (95% confidence interval: −1.79, 0.0; P = 0.06); therefore, the primary endpoint was not met. During 360-d follow-up, five of 24 participants in the control group developed a total of 10 severe adverse events, four of which were liver related, and three deaths (two liver related), whereas no liver-related severe adverse events or deaths occurred in the treatment group. Although no differences were observed in biomarkers or HRQoL, exploratory analysis showed anti-inflammatory serum cytokine profiles after macrophage infusion. This study reinforces the safety and potential efficacy of macrophage therapy in cirrhosis, supporting further investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-024-03406-8

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 CONSORT diagram of the participant flow. The diagram is split by triple-infusion, single-infusion and control groups.
Fig. 1 CONSORT diagram of the participant flow. The diagram is split by triple-infusion, single-infusion and control groups.CC BY · PubMed Central
Fig. 2 Baseline to day 90 ΔMELD score. a, Box plot of ΔMELD score, split by treatment allocation. Control (CTRL) group: n = 24 participants. CELLS group: n = 27 participants (includes both single-infusion and triple-infusion participants). Box plots are defined as first to third quartile (Q1, Q3), with center line representing the median. Whiskers extend to the lowest/highest values no further than 1.5× IQR from Q1/Q3, as appropriate. b, Plot of total cell dose (n × 109) versus ΔMELD. Participants are color coded by dominant etiology (ALD, MASLD or Other). This plot includes all participants who received at least one infusion.
Fig. 2 Baseline to day 90 ΔMELD score. a, Box plot of ΔMELD score, split by treatment allocation. Control (CTRL) group: n = 24 participants. CELLS group: n = 27 participants (includes both single-infusion and triple-infusion participants). Box plots are defined as first to third quartile (Q1, Q3), with center line representing the median. Whiskers extend to the lowest/highest values no further than 1.5× IQR from Q1/Q3, as appropriate. b, Plot of total cell dose (n × 109) versus ΔMELD. Participants are color coded by dominant etiology (ALD, MASLD or Other). This plot includes all participants who received at least one infusion.CC BY · PubMed Central
Fig. 3 Longitudinal cytokine measurements. Box plots of anti-inflammatory and pro-inflammatory cytokines with significant effects due to macrophage treatment, split by timepoint and treatment. Control (CTRL) group: n = 23 participants (except d360 in all cytokines n = 21). CELLS group: n = 26 participants. Repeated ANOVA, two-sided, with pairwise two-sided post hoc tests. Box plots are defined as first to third quartile (Q1, Q3), with center line representing the median. Whiskers extend to the lowest/highest values no further than 1.5× IQR from Q1/Q3, as appropriate. d, day.
Fig. 3 Longitudinal cytokine measurements. Box plots of anti-inflammatory and pro-inflammatory cytokines with significant effects due to macrophage treatment, split by timepoint and treatment. Control (CTRL) group: n = 23 participants (except d360 in all cytokines n = 21). CELLS group: n = 26 participants. Repeated ANOVA, two-sided, with pairwise two-sided post hoc tests. Box plots are defined as first to third quartile (Q1, Q3), with center line representing the median. Whiskers extend to the lowest/highest values no further than 1.5× IQR from Q1/Q3, as appropriate. d, day.CC BY · PubMed Central
Extended Data Fig. 1 Isolation of monocytes and manufacturing of the MATCH01 product. a-d, Process robustness for manufacturing of the MATCH01 product. All products manufactured in the 23-participant single-dose group and the 3-participant triple-dose group. a-b Leukapheresis starting material (a, Total Nucleated Cell (TNC) collected from steady state leukapheresis from male and female participants * p = 0.0398; b, CD14+ monocyte content in steady state leukapheresis ** p = 0.0069). Two-sided unpaired t-test. c-d, Performance in manufacturing process (c, yield of CD14+ cells from the CliniMACS Prodigy selection procedure; d, final process yield of manufactured product for infusion, as a percentage of input CD14+ monocytes. ns = no significant difference by two-sided unpaired t-test. e-f, Phenotype of macrophages in final manufactured product for infusion, compared between alcohol and non-alcohol-related liver disease groups, 19 consecutive participants from single dose series. Two-sided unpaired t-tests. e, Expression of CD14 and CD16 in infused product between alcohol and non-alcohol-related liver disease groups. f, Change in relative expression of CD163, CD169 and CCR2 molecules on final product macrophages, compared to input monocytes. In all panels, bars represent group means.
Extended Data Fig. 1 Isolation of monocytes and manufacturing of the MATCH01 product. a-d, Process robustness for manufacturing of the MATCH01 product. All products manufactured in the 23-participant single-dose group and the 3-participant triple-dose group. a-b Leukapheresis starting material (a, Total Nucleated Cell (TNC) collected from steady state leukapheresis from male and female participants * p = 0.0398; b, CD14+ monocyte content in steady state leukapheresis ** p = 0.0069). Two-sided unpaired t-test. c-d, Performance in manufacturing process (c, yield of CD14+ cells from the CliniMACS Prodigy selection procedure; d, final process yield of manufactured product for infusion, as a percentage of input CD14+ monocytes. ns = no significant difference by two-sided unpaired t-test. e-f, Phenotype of macrophages in final manufactured product for infusion, compared between alcohol and non-alcohol-related liver disease groups, 19 consecutive participants from single dose series. Two-sided unpaired t-tests. e, Expression of CD14 and CD16 in infused product between alcohol and non-alcohol-related liver disease groups. f, Change in relative expression of CD163, CD169 and CCR2 molecules on final product macrophages, compared to input monocytes. In all panels, bars represent group means.CC BY · PubMed Central
Extended Data Fig. 2 Intra-patient robustness of macrophage manufacturing process. Three participants (P1, P2, P3) donated leukapheresis three times at monthly intervals and received infusions of freshly manufactured macrophages. a, The total leukocyte content and the b, CD14 content of each donation remained constant between each donation timepoint. c, CD14+ selection efficiency and d, conversion to macrophages in the final product remained constant between each donation and comparable to the main group (Extended Data Fig. 1). e, Accordingly, the participants received infusions of comparable numbers of macrophages on each occasion, even though the product was manufactured in a unique production run per product.
Extended Data Fig. 2 Intra-patient robustness of macrophage manufacturing process. Three participants (P1, P2, P3) donated leukapheresis three times at monthly intervals and received infusions of freshly manufactured macrophages. a, The total leukocyte content and the b, CD14 content of each donation remained constant between each donation timepoint. c, CD14+ selection efficiency and d, conversion to macrophages in the final product remained constant between each donation and comparable to the main group (Extended Data Fig. 1). e, Accordingly, the participants received infusions of comparable numbers of macrophages on each occasion, even though the product was manufactured in a unique production run per product.CC BY · PubMed Central
Extended Data Fig. 3 Plot of the baseline to day 360 changes in MELD score (∆MELD). Individual line plots are shown for each participant. Treatment allocation is separated into participants that received three cell infusions, single cell infusions and control (standard of care).
Extended Data Fig. 3 Plot of the baseline to day 360 changes in MELD score (∆MELD). Individual line plots are shown for each participant. Treatment allocation is separated into participants that received three cell infusions, single cell infusions and control (standard of care).CC BY · PubMed Central
Extended Data Fig. 4 Summary of anti- and pro-inflammatory cytokine data. Heatmap of median log fold change for measurements of anti- and pro-inflammatory cytokines, compared to day 0, in treated and untreated groups.
Extended Data Fig. 4 Summary of anti- and pro-inflammatory cytokine data. Heatmap of median log fold change for measurements of anti- and pro-inflammatory cytokines, compared to day 0, in treated and untreated groups.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 71

Metadata

Authors
Brennan, P. N., MacMillan, M., Manship, T., Moroni, F., Glover, A., Troland, D., MacPherson, I., Graham, C., Aird, R., Semple, S. I. K., Morris, D. M., Fraser, A. R., Pass, C., McGowan, N. W. A., Turner, M. L., Manson, L., Lachlan, N. J., Dillon, J. F., Kilpatrick, A. M., Campbell, J. D. M., Fallowfield, J. A., & Forbes, S. J.
Affiliations
  • University of Dundee (GB)
  • MRC Centre for Regenerative Medicine (GB)
  • Edinburgh Royal Infirmary (GB)
  • Aberdeen Royal Infirmary (GB)
  • Scottish National Blood Transfusion Service (GB)
  • University of Edinburgh (GB)
  • Glasgow Royal Infirmary (GB)
  • Centre for Inflammation Research (GB)
Corresponding author
Forbes, Stuart J.
Venue
Nature Medicine
Published
2025-01-10
Volume
31
Issue
3
Pages
979-987
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4406231919
Cited by
66
References
51
Citations by year
2026: 35 · 2025: 31
FWCI
37.10
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (publishedVersion, cc-by)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
Funders
RCUK | Medical Research Council (MR/M007588/1)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Keywords
liver cirrhosis, monocyte-derived macrophages, bone marrow-derived macrophages, MELD score, liver fibrosis, liver regeneration, anti-inflammatory cytokines, health-related quality of life, adverse events, compensated cirrhosis
MeSH terms
Adult, Aged, Female, Humans, Liver Cirrhosis, Macrophages, Male, Middle Aged, Quality of Life, Transplantation, Autologous, Biomarkers, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial. https://app.cochat.ai/papers/10.1038/s41591-024-03406-8
The paper
Brennan, P. N., MacMillan, M., Manship, T., Moroni, F., Glover, A., Troland, D., MacPherson, I., Graham, C., Aird, R., Semple, S. I. K., Morris, D. M., Fraser, A. R., Pass, C., McGowan, N. W. A., Turner, M. L., Manson, L., Lachlan, N. J., Dillon, J. F., Kilpatrick, A. M., . . . Forbes, S. J. (2025). Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03406-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.